Skip to main content
. 2021 Jun 2;2021:9944880. doi: 10.1155/2021/9944880

Figure 5.

Figure 5

Proposal of a proinflammatory pathway inhibited by empagliflozin (SGLT2 inhibitor) and gemigliptin (DPP-4 inhibitor) in LPS-activated RAW 264.7 macrophages.